The AST/ALT (De Ritis) Ratio Predicts Survival in Patients with Oral and Oropharyngeal Cancer.
AST/ALT (DeRitis) ratio
alanine aminotransaminase (ALT)
aminotransferases
aspartate aminotransaminase (AST)
oral and oropharyngeal cancer
prognostic factor
radiotherapy
survival
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
19 Nov 2020
19 Nov 2020
Historique:
received:
20
10
2020
revised:
11
11
2020
accepted:
16
11
2020
entrez:
24
11
2020
pubmed:
25
11
2020
medline:
25
11
2020
Statut:
epublish
Résumé
Aminotransaminases, including aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT), are strongly involved in cancer cell metabolism and have been associated with prognosis in different types of cancer. The purpose of the present study was to evaluate the prognostic significance of the pre-treatment AST/ALT ratio in a large European cohort of patients with oral and oropharyngeal squamous cell cancer (OOSCC). Data from 515 patients treated for OOSCC at a tertiary academic center from 2000-2017 were retrospectively analyzed. Levels of AST and ALT were measured prior to the start of treatment. Uni- and multivariate Cox regression analyses were applied to evaluate the prognostic value of the AST/ALT ratio for cancer-specific survival (CSS) and overall survival (OS), survival rates were calculated. Univariate analyses showed a significant association of the AST/ALT ratio with CSS (hazard ratio (HR) 1.71, 95% confidence interval (CI) 1.38-2.12;
Identifiants
pubmed: 33228184
pii: diagnostics10110973
doi: 10.3390/diagnostics10110973
pmc: PMC7699507
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Cancer Res Ther. 2008 Jan-Mar;4(1):21-5
pubmed: 18417898
Exp Cell Res. 2015 Jul 1;335(1):91-8
pubmed: 25907297
Dis Colon Rectum. 1994 Dec;37(12):1219-27
pubmed: 7995147
Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
PLoS One. 2016 Oct 12;11(10):e0164057
pubmed: 27732629
Urol Oncol. 2016 Sep;34(9):417.e9-417.e15
pubmed: 27180325
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Anticancer Res. 2018 Jul;38(7):4179-4185
pubmed: 29970547
Clin Cancer Res. 2010 Feb 1;16(3):1008-15
pubmed: 20103685
Mol Cancer. 2019 Mar 11;18(1):38
pubmed: 30857539
J Clin Oncol. 2013 Dec 20;31(36):4550-9
pubmed: 24248688
Br J Cancer. 2010 Sep 7;103(6):870-6
pubmed: 20717110
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Hepatogastroenterology. 2013 Nov-Dec;60(128):1892-5
pubmed: 24719923
Clin Genitourin Cancer. 2017 Oct;15(5):598-604
pubmed: 28495053
Clin Biochem Rev. 2013 Nov;34(3):117-30
pubmed: 24353357
Int Urol Nephrol. 2017 Aug;49(8):1391-1398
pubmed: 28550473
BMC Urol. 2019 Jan 24;19(1):10
pubmed: 30678673
J Urol. 2015 Jul;194(1):30-5
pubmed: 25623738
Gene. 2019 Jul 20;706:131-139
pubmed: 31055021
Nat Rev Cancer. 2011 May;11(5):325-37
pubmed: 21508971
Clin Chim Acta. 1957 Feb;2(1):70-4
pubmed: 13447217
PLoS One. 2016 Jun 30;11(6):e0158697
pubmed: 27362659
World J Urol. 2015 Oct;33(10):1467-73
pubmed: 25475065
Br J Cancer. 2008 Sep 16;99(6):883-93
pubmed: 19238630